ClinicalTrials.gg
Sign In
CompletedNCT05016687Updated Mar 23, 2022

First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.

A Phase 1 interventional study of CUR-N399 and Placebo in Pulmonary Disease, Chronic Obstructive, Enterovirus Infections and Rhinovirus, sponsored by Curovir AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Curovir AB · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the trial is to evaluate CUR-N399, a PI4KB inhibitor, in a first-in-human trial to evaluate the safety, tolerability and pharmacokinetics profile of single and multiple ascending doses in healthy adults.

In the SAD part of the trial, single oral doses of CUR-N399 will be administered in 5 sequential cohorts. In all cohorts, safety and PK will be assessed before and after dose. Exploratory nasopharyngeal swab for assessment of airway infectants will be performed before dose and in the morning of Day 3.

In SAD part Cohort 4: A urine sample will be taken from the first morning void on Day 1 and urine will be collected for potential quantification of CUR-N399 (and metabolites) during the first 24 hours post-dose.

The MAD part of the trial will explore multiple ascending dosing of CUR-N399. The initial dose, dose escalation and dosing schedule will be based on emerging knowledge of safety, tolerability and PK of CUR-N399 observed in the SAD part of the trial. CUR-N399 will be administered in 3 sequential cohorts. An additional MAD cohort will evaluate CUR-N399 in older adults ≥65 years.

All SAD and MAD cohorts will evaluate 8 subjects. Within each cohort, subjects will be randomised in a 3:1 ratio to receive CUR-N399 (n=6) or placebo (n=2) in a blinded fashion.

02

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
  • Enterovirus Infections
  • Rhinovirus
03

In context

Pulmonary Disease, Chronic Obstructive

4,253 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 707 are open to participants now.

This study's enrollment of 74 is close to the median of 70 across 3,008 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

This is the only study on the registry with Curovir AB as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give written informed consent for participation in the study.
  2. Part I and IIa: Healthy male or female subject aged 18-50 years inclusive. Part IIb: Healthy male or female subject aged ≥65 years inclusive.
  3. Body Mass Index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2.
  4. Clinically normal medical history, physical findings, vital signs, ECG and laboratory values at the time of screening, as judged by the Investigator.
  5. WOCBP must practice abstinence (only allowed when this is the preferred and usual lifestyle of the subject) or must agree to use a highly effective method of contraception with a failure rate of \< 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD] or intrauterine hormone-releasing system [IUS]) from at least 4 weeks prior to dose to 4 weeks after last dose. Female subjects must refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.

Women of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone [FSH] 25-140 IE/L is confirmatory).

Male subjects must be willing to use condom or be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP. Their female partner of child-bearing potential must use contraceptive methods with a failure rate of \< 1% to prevent pregnancy (see above). -

Exclusion criteria

Exclusion Criteria:

  1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  2. Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
  3. Current or history of gastrointestinal bleedings, inflammatory bowel disease, irritable bowel syndrome or coeliac disease, as judged by the Investigator.
  4. Malignancy within the past 5 years with the exception of in situ removal of basal cell carcinoma.
  5. Any planned major surgery within the duration of the study.
  6. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV.
  7. After 10 minutes supine rest at the time of screening, any vital signs values outside the following ranges: Part I, IIa: Systolic blood pressure \<90 or >140 mmHg, or Diastolic blood pressure \<50 or >90 mmHg, or Pulse \<40 or >90 beats per minute (bpm) Part IIb: Systolic blood pressure \<90 or >160 mmHg, or Diastolic blood pressure \<50 or >100 mmHg, or Pulse \<40 or >90 bpm
  8. Prolonged QTcF (>450 ms for men, >470 ms for women), cardiac arrhythmias or any clinically significant abnormalities in the resting ECG at the time of screening, as judged by the Investigator.
  9. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to CUR-N399.
  10. Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator. NB. The use of a stable dose of levothyroxine is allowed for subjects in Part IIb.
  11. Any use of omeprazole products (or products of the same drug class) within 2 weeks prior to the (first) administration of IMP, at the discretion of the Investigator.
  12. Planned treatment or treatment with another investigational drug within 3 months prior to Day -1. Subjects consented and screened but not dosed in previous Phase I studies are not excluded.
  13. Current smokers or users of nicotine products. Irregular use of nicotine (e.g. smoking, snuffing, chewing tobacco) less than three times per week is allowed before screening visit.
  14. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to (first) administration of the IMP.
  15. History or presence of alcohol abuse or excessive intake of alcohol, as judged by the Investigator.
  16. Presence or history of drug abuse, as judged by the Investigator.
  17. History of, or current use of, anabolic steroids.
  18. Excessive caffeine consumption defined by a daily intake of >5 cups of caffeine containing beverages.
  19. Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the three months prior to screening.
  20. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Experimental Part I Cohort 1-5: CUR-N399

    Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.

    Drug: CUR-N399

  • Placebo comparator
    Experimental Part I Cohort 1-5: Placebo

    Healthy subjects will receive Placebo to match treatment of CUR-N399.

    Drug: Placebo

  • Experimental
    Experimental Part IIa Cohort 1-3: CUR-N399

    Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.

    Drug: CUR-N399

  • Placebo comparator
    Experimental Part IIa Cohort 1-3: Placebo

    Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.

    Drug: Placebo

  • Experimental
    Experimental Part IIb: CUR-N399

    Healthy subjects \>/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.

    Drug: CUR-N399

  • Placebo comparator
    Experimental Part IIb: Placebo

    Healthy subjects \>/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.

    Drug: Placebo

Interventions

  • DrugCUR-N399

    CUR-N399 will be administered as oral capsules.

  • DrugPlacebo

    Placebo capsules matching CUR-N399 will administered.

06

What researchers measure

Primary outcomes

  1. All Parts: Adverse events (AE)

    • Incidence (frequency, intensity and seriousness) of AEs

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  2. All Parts: Clinically significant changes in electrocardiograms (ECGs)

    • Single 12-lead ECG will be recorded in supine position after 10 minutes of rest using an ECG machine. HR and PR, QRS, QT and QTcF intervals will be recorded.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  3. All Parts: Clinically significant changes in vital signs (pulse)

    • Pulse will be recorded.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  4. All Parts: Clinically significant changes in vital signs (blood pressure)

    • Blood pressure will be recorded.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  5. All Parts: Clinically significant changes in safety laboratory parameters (clinical chemistry)

    • Blood samples for analysis of clinical chemistry parameters: * Alanine aminotransferase (ALT) * Albumin * Alkaline phosphatase (ALP) * Aspartate aminotransferase (AST) * Bilirubin (total and conjugated) * Calcium * Cholesterol (HDL, LDL, total) * Creatinine (estimated Glomerular Filtration Rate \[eGFR\] included) * C-reactive protein (CRP) * Glucose * Lactate dehydrogenase (LD) * Phosphate * Potassium * Sodium * Triglycerides * Urea will be collected and sent to the certified clinical chemistry laboratory and analysed by routine analytical methods.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  6. All Parts: Clinically significant changes in safety laboratory parameters (heamatology)

    • Blood samples for analysis of haematology parameters: * Haematocrit * Haemoglobin (Hb) * Platelet count * Red blood cell (RBC) count * White blood cell (WBC) count with differential count will be collected and sent to the certified clinical chemistry laboratory and analysed by routine analytical methods.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  7. All Parts: Clinically significant changes in safety laboratory parameters (coagulation)

    • Blood samples for analysis of coagulation parameters: * Activated Partial Thromboplastin Time (APTT) * Prothrombin Complex International Normalised Ratio (PK\[INR\]) will be collected and sent to the certified clinical chemistry laboratory and analysed by routine analytical methods.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

  8. All Parts: Clinically significant changes in physical examinations

    • Routine physical examinations will be performed. Incidence of clinically significant changes will be recorded.

    Time frame: From start of treatment Day 1 to End of Study (Day 8 SAD and Day 14 MAD)

Secondary outcomes

  1. All Parts: Pharmacokinetics (PK) of CUR-N399 (AUC0-t)

    Area under the curve (AUC) from time 0 to time t (AUC0-t)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  2. All Parts: Pharmacokinetics (PK) of CUR-N399 (AUC0-∞)

    AUC from time 0 to infinity (AUC0-∞)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  3. All Parts: Pharmacokinetics (PK) of CUR-N399 (T½)

    Terminal half-life (T½)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  4. All Parts: Pharmacokinetics (PK) of CUR-N399 (Cmax)

    Observed maximum plasma concentration (Cmax)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  5. All Parts: Pharmacokinetics (PK) of CUR-N399 (Tmax)

    Time to Cmax (Tmax)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  6. All Parts: Pharmacokinetics (PK) of CUR-N399 (dose proportionality)

    Dose proportionality (based on AUC and Cmax)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  7. All Parts: Pharmacokinetics (PK) of CUR-N399 (CL/F)

    Apparent total body clearance following extravascular administration (CL/F)

    Time frame: Pre-dose Day 1 to 48 hours post last dose (Day 3 SAD and Day 9 MAD respectively)

  8. All Parts: Pharmacokinetics (PK) of CUR-N399 (Vz/F)

    Apparent volume of distribution following extravascular administration (Vz/F)

    Time frame: Pre-dose Day 1 to 48 post last dose (Day 3 SAD and Day 9 MAD respectively)

  9. Part II a+b: Pharmacokinetics (PK) of CUR-N399 (AUCtau) for MAD groups

    AUC for the dosing interval (AUCtau)

    Time frame: After first dose (Day 1) and up to 48 hours post last dose (Day 9)

  10. Part II a+b: Pharmacokinetics (PK) of CUR-N399 (Ctrough) for MAD groups

    Observed concentration at the end of a dosing interval (Ctrough)

    Time frame: Pre-dose administration on Days 2 to 7

  11. Part II a+b: Pharmacokinetics (PK) of CUR-N399 (Accumulation ratio) for MAD groups

    Accumulation ratio

    Time frame: Day 1 to 48 hours post last dose (Day 9)

Other outcomes

  1. All parts: Nasopharyngeal swabs to evaluate airway infectants

    Nasopharyngeal swab samples will be taken to evaluate the presence and levels of a panel of airway infectants: * Respiratory syncytial virus * Metapneumovirus * Influenza a, b * All 4 Coronaviruses * Adenovirus * Parainfluenza virus 1, 2, 3 * Mycoplasma * Clostridium difficile * Pneumococci

    Time frame: Pre-dose Day -1 to Day 3

  2. Part I Cohort 4: CUR-N399 (and metabolites) in urine in SAD Cohort

    Potential quantification of unchanged CUR-N399 and metabolites in urine

    Time frame: Pre-dose Day 1 to Day 3

  3. Part II a+b: Metabolic profile of CUR-N399 in plasma in MAD groups

    Potential future metabolite identification in plasma and possible comparison with metabolite exposure in pre-clinical safety studies (metabolites in safety testing \[MIST\])

    Time frame: Day 1 to Day 9

  4. Part II a+b: To assess age-related differences in safety of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    To assess age related incidence (frequency and severity) of AEs

    Time frame: From Start of Treatment Day 1 to End of Study Day 14

  5. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (AUC0-t) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    To assess age related differences in AUC0-t

    Time frame: Pre-dose to 48 hours after first dose (Day 3) and after last dose Day 7 to 48 hours post-dose (Day 9)y 1 to 24 hours post last dose Day 8

  6. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (AUCtau) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    AUC for the dosing interval (AUCtau)

    Time frame: Pre-dose Day 1 to 48 hours post last dose Day 9

  7. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (T½) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Terminal half-life (T½)

    Time frame: After first dose Day 1 and up to 48 hours after last dose Day 9

  8. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (Tmax) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Time to Cmax (Tmax)

    Time frame: Up to 48 hours after first dose Day 1 (Day 3) and last dose Day 7 (Day 9)

  9. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (Cmax) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Observed maximum plasma concentration (Cmax)

    Time frame: Up to 48 hours after first dose Day 1 (Day 3) and last dose Day 7 (Day 9)

  10. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (Dose proportionality) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Dose proportionality (based on AUCtau and Cmax)

    Time frame: Up to 48 hours after first dose Day 1 (Day 3) and last dose Day 7 (Day 9)

  11. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (Ctrough) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Observed concentration at the end of a dosing interval (Ctrough)

    Time frame: Pre-dose of last dose Day 7

  12. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (CL/F) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Apparent total body clearance following extravascular administration (CL/F)

    Time frame: Up to 48 hours post last dose Day 7 (Day 9)

  13. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (Vz/F) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Apparent volume of distribution following extravascular administration (Vz/F)

    Time frame: Up to 48 hours post last dose Day 7 (Day 9)

  14. Part II a+b: To assess age-related differences in pharmacokinetic (PK) profile (Accumulation ratio) of two age groups 18-55 vs ≥65 year in MAD Cohort with Older adults

    Accumulation ratio

    Time frame: Up to 48 hours post last dose Day 7 (Day 9)

07

Study locations

1 site
  • CTC Clinical Trial Consultants AB
    Uppsala, SE-75185, Sweden
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05016687
Lead sponsor
Curovir AB
Collaborators
CTC Clinical Trial Consultants AB
Responsible party
Sponsor
First posted
Aug 23, 2021
Start date
Jul 22, 2021
Primary completion
Mar 22, 2022
Completion
Mar 22, 2022
Last update
Mar 23, 2022

Study contacts

Nina Lindblom, PhD
study director · Curovir AB

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Pulmonary Disease, Chronic Obstructive →

Start the discussion